Back | Next |
home / stock / blrx / blrx message board
Subject | By | Source | When |
---|---|---|---|
BioLine RX ($BLRX) | midastouch017 | investorshub | 04/10/2023 9:16:17 AM |
Agreed, definitely manipulation going on. | Spideyboy | investorshub | 04/10/2023 3:47:14 AM |
1.0100+0.0475 (+4.94%) | midastouch017 | investorshub | 04/06/2023 6:29:07 PM |
IMO, already today $BLRX will reach the $1.00 mark. | midastouch017 | investorshub | 04/05/2023 9:18:19 AM |
Again this run has been very surprising. | midastouch017 | investorshub | 04/04/2023 1:14:15 PM |
Again this run has been very surprising. Looks | Spideyboy | investorshub | 04/04/2023 11:06:24 AM |
Some +7% to over $ 1.00 | midastouch017 | investorshub | 04/03/2023 4:54:47 PM |
I have a feeling $BLRX will get over | midastouch017 | investorshub | 04/03/2023 12:02:35 PM |
If we can get over $1 in the | kidscosttoomuch | investorshub | 03/31/2023 7:15:09 PM |
Anyway, Spideyboy i have a smallish | midastouch017 | investorshub | 03/31/2023 1:45:26 PM |
Hi Midas, | Spideyboy | investorshub | 03/31/2023 11:43:39 AM |
0.8957+0.0357 (+4.15%) | midastouch017 | investorshub | 03/29/2023 4:59:48 PM |
BioLineRx Ltd. (NASDAQ:BLRX) Q4 2022 Earnings Call Transcript | midastouch017 | investorshub | 03/25/2023 7:27:22 AM |
0.7997+0.0298 (+3.8706%) | midastouch017 | investorshub | 03/24/2023 3:42:03 PM |
Just checking my numbers again on the cash | Spideyboy | investorshub | 03/22/2023 2:17:49 PM |
Hi Spidey, | midastouch017 | investorshub | 03/22/2023 1:46:56 PM |
BioLineRx Reports 2022 Financial Results and Recent Corporate | midastouch017 | investorshub | 03/22/2023 1:04:27 PM |
Hi Midas, | Spideyboy | investorshub | 03/22/2023 9:22:14 AM |
Addendum: biolinerx FY 2022 Earnings Preview | midastouch017 | investorshub | 03/21/2023 5:52:04 PM |
Maybe someone leaked good news about earnings? | midastouch017 | investorshub | 03/21/2023 5:44:59 PM |
News, Short Squeeze, Breakout and More Instantly...
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD) PR Newswire - Investigator-initiated study in...
Orkla ASA ADR (ORKLY) is expected to report for Q1 2024 Cosmos Health Inc. (COSM) is expected to report $-0.14 for Q1 2024 Basilea Pharmaceutica AG Registered Shares (BPMUF) is expected to report for Q1 2024 DCC Plc (DCCPF) is expected to report for Q4 2024 Datatec Ltd ADR (DTTLY)...
BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting PR Newswire New analysis of biopsy samples demonstrate...